



香港交易所 (0388 HK)

上日收市價：400.60 港元

支持位：388.20 港元/ 380.80 港元

阻力位：431.00 港元/ 449.60 港元

技術分析：

主导的上升趋势已迎来重大结构性里程碑，价格强势向上穿透并封盘于缺口阻力位之上，将先前的上方筹码供给成功转化为经确认的基线支撑。顺势动能得到了 MACD 指标的充分印证，该指标已翻红转正并保持向上斜率，映射出买盘意愿的持续释放。只要这一新确立的支撑边界不被下破，技术面运行轨迹将保持强烈的多头拓展取向。

預期平均時限：約 2 週

巨子生物 (2367 HK)

上日收市價：29.60 港元

支持位：27.84 港元/ 26.38 港元

阻力位：31.82 港元/ 36.24 港元

技術分析：

盘面架构通过成功守住极性转换的需求水平，完整保留了其结构性支撑地基，使价格运行轨迹完美对齐了对局部高水位的再次下击。震荡指标分析高度契合这一积极的图表几何形态，上升的 MACD 信号映射出动能正处于扩张阶段，且上方几乎不存在技术性阻碍。从统计概率视角来看，防守有力的技术地基与加速中的动能形成共振，显著增加了价格突破高点并开启延伸性拉升的胜率。

預期平均時限：約 2 週



分析員

大中華研究團隊

research-hk@uobkh.com

譚文漢，特許財務分析師

munhon.tham@uobkh.com

+852 2236 6799

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at the following link:
<https://research-api.uobkayhian.com/assets/disclaimer/0e6d602f-adeb-45f8-9dea-5d5591daae87> or by scanning the QR code below:



The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."